Chime Biologics
Chime Biologics is a privately held Chinese CDMO providing end-to-end biologics development and manufacturing — from cell line development through commercial drug substance and drug product supply — serving global biotech and pharmaceutical clients across 30+ countries via its Wuhan KUBio modular facility and Basel European Innovation Hub.
- Company typePrivate
- Founded2013
- HeadquartersWuhan, China
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Chime Biologics does
Chime Biologics is a privately held biologics contract development and manufacturing organization (CDMO) founded in 2013 and headquartered in Wuhan, China, with additional operations in Shanghai (China Innovation Hub), Basel (European Innovation Hub opened June 2025), and sales offices in San Diego, Boston, and Paris. The company operates the world's first KUBio modular biopharmaceutical factory built with GE/Cytiva technology, using single-use bioreactors at 50L, 200L, 500L, and 2000L cGMP scales to manufacture monoclonal antibodies, bispecific antibodies, fusion proteins, conjugated proteins, enzymes, and vaccines. Its facilities are designed to meet NMPA, EMA, US FDA, and EU PIC/S GMP standards, and the company reports more than 70 successful 2000L GMP production batches and clinical material supply to clients across 30+ countries.
The company's service portfolio spans the full biologics development lifecycle: cell line development, process development, protein science, technology transfer, drug substance manufacturing, drug product manufacturing (including liquid fill, lyophilized fill and pre-filled syringe fill in isolators), quality systems, regulatory support, project management, and data integrity. In November 2025 it launched the Chime AI Platform in partnership with Opq Therapeutics, adding AI-enabled target screening, antibody design and optimization, AI-enhanced cell line development, and AI-integrated rapid CMC as adjacent offerings. The business operates on professional-services contracts with biotech and biopharmaceutical clients, priced project-by-project, and pursues co-development and strategic partnerships (e.g., Polpharma Biologics, SunRock Biopharma, Domain Therapeutics, Daewoong Pharmaceutical, Libang Pharmaceuticals, TNAX Biopharma) as a parallel go-to-market channel.
Chime generates revenue through negotiated CDMO contracts and strategic collaborations with global biotech and biopharmaceutical clients. Pricing is quote-based and varies with scope, scale and development stage, typical of the contract manufacturing industry. The company is scaling aggressively: a US$190 million Series A+ in May 2024 (led by VMS Group with Fidelity International and Panacea Venture) and a December 2025 Optics Valley Financial Holdings round are funding capacity expansion toward 140,000+ liters over five years, while the Chime Innovation Alliance and Basel hub extend its commercial reach across China, Europe, and APAC.
Chime Biologics firmographics
Firmographics- Name
- Chime Biologics
- Legal name
- Chime Biologics (Wuhan) Co., Ltd.
- Website
- https://chimebiologics.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Chime Biologics is a privately held Chinese CDMO providing end-to-end biologics development and manufacturing — from cell line development through commercial drug substance and drug product supply — serving global biotech and pharmaceutical clients across 30+ countries via its Wuhan KUBio modular facility and Basel European Innovation Hub.
- Ownership category
- akta.pro rank
Chime Biologics industry classification
Industry- Product category
- Biopharmaceutical Contract Manufacturing (CDMO)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Biologic API/Drug Substance Manufacturing Services (HLAAAKAA), Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
Keywords
Where Chime Biologics is headquartered
LocationHeadquarters
- HQ city
- Wuhan
- HQ country
- China
- HQ region
- Asia
Offices6 records
Markets served
Chime Biologics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Revenue model
- CDMO Contract Manufacturing Services: Full-suite contract development and manufacturing organization (CDMO) services including cell line development, process development, protein science, technology transfer, drug substance manufacturing, drug product manufacturing, quality control/assurance, regulatory support, and project management. Revenue generated through service contracts and manufacturing agreements with biotech and pharmaceutical clients across the development lifecycle from preclinical through commercial stages.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Chime Biologics product offering
Product offeringCore offering
Chime Biologics is a global Contract Development and Manufacturing Organization (CDMO) that provides end-to-end biologics manufacturing services for biotech and pharmaceutical companies. The company offers services spanning cell line development, process development, drug substance manufacturing (50L–2000L), drug product manufacturing, technology transfer, quality control, and regulatory support from pre-clinical through commercial stages. Its operations leverage the world's first GE KuBio modular biopharmaceutical manufacturing facility using single-use bioprocessing technology, complemented by the newly launched Chime AI Platform for AI-driven biologics discovery and development.
Product overview
Chime Biologics is a leading global CDMO (Contract Development and Manufacturing Organization) providing end-to-end biologics manufacturing services from pre-clinical support through clinical and commercial manufacturing. The portfolio consists of core service modules including Cell Line Development, Process Development, Protein Science Group, Technology Transfer, Drug Substance Manufacturing (M-DS), Drug Product Manufacturing (M-DP), Quality System, Regulatory Support, Project Management, and Data Integrity. These services are powered by key technology platforms: the KUBio modular biopharmaceutical factory (world's first modular facility using single-use bioreactors from GE/Cytiva), and the Chime AI Platform for AI-driven biologics development. Manufacturing capabilities span scales from 50L to 2000L bioreactors for diverse molecule types including monoclonal antibodies, bispecific antibodies, fusion proteins, conjugated proteins, enzymes, and vaccines.
Differentiator
Problem solved
Functional benefit
Products and services
- End-to-End CDMO Services
Quantifiable outcome
- Successfully completed over 70 batches of 2000L GMP production
- +2 more outcomes
Companies that use Chime Biologics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Chime Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
Chime Biologics partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered major, regional, strategic, core and supporting.
- Beijing Libang Pharmaceutical (Libang Pharmaceuticals)majorStrategic collaboration to develop a biosimilar to Amgen's Blincyto (blinatumomab) for global markets. Chime Biologics will leverage its GMP manufacturing platform and regulatory expertise to support the biosimilar development program.
- TNAX BiopharmaregionalStrategic collaboration marking Chime Biologics' first partnership in Japan. TNAX Biopharma is a Japanese biotech company.
- Opq Therapeutics (奥泊生科)strategicStrategic collaboration on AI-driven biologics discovery. Opq provides advanced AI technology for target screening, antibody design, and optimization while Chime provides CMC capabilities. Co-founders include Nobel Laureate Michael Levitt.
- SunRock BiopharmamajorStrategic collaboration to develop SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD) with potential expansion into other immune-mediated inflammatory indications. SunRock Biopharma is a Spanish biotech company focused on next-generation therapeutic antibodies.
- Superlab SuissecoreHost facility for Chime Biologics' European Innovation Hub in Basel. Superlab Suisse provides laboratory space and infrastructure enabling Chime's operations in the heart of Europe's biotech ecosystem.
- Basel Area Business and InnovationsupportingBasel Area Business and Innovation is the official economic development agency for the Basel area. They support and promote the biotech ecosystem and welcomed Chime Biologics' establishment of European Innovation Hub in Basel.
- Chime Innovation Alliance PartnerscoreAlliance of leading Chinese biotech service providers providing one-stop solutions for customers from drug discovery through preclinical, clinical, and commercial stages. Partner companies include Sepax Bioscience, AnLing, Alioth Biotech, NanoMicro, Duoning Biotech, Lisure, and others.
- Japan-China Bio-Innovation Ecosystem Forum PartnerssupportingCo-organized with Duoning Biotech and Lisure to promote innovation, collaboration, and investment between Japan and China in the biopharmaceutical industry.
- Polpharma BiologicsmajorStrategic partnership with Poland-based Polpharma Biologics to support end-to-end development and manufacture of a biosimilar product for the global market. Chime provides integrated support from IND stage through commercial supply. Polpharma has two biosimilars approved by FDA and EMA.
- Domain TherapeuticsmajorManufacturing agreement for DT-7012, a novel anti-CCR8 antibody for cancer immunotherapy. Chime provides cell line development, process development, scale-up, and Phase I GMP clinical manufacturing. DT-7012 is a potential best-in-class Treg-depleting antibody.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Chime Biologics competitors and assessment
Company assessmentBroad incumbents
- Lonza: Swiss-based global CDMO with extensive biologics manufacturing capabilities across mammalian and microbial platforms. Serves as the dominant Western incumbent in biologics CDMO, competing with Chime for large-pharma and biotech contracts across multiple regulatory jurisdictions.
- Catalent: Large US-headquartered CDMO with biologics fill-finish, cell line, and biomanufacturing capabilities as part of a broader services portfolio. Overlaps with Chime on biologics drug substance and drug product manufacturing while also serving injectables, oral, and inhalation delivery.
Direct peers
- Samsung Biologics: Korean-based global biologics CDMO with large-scale cGMP manufacturing capacity (expanding toward ~1M liters) and full lifecycle services from clinical to commercial supply. Direct competitor for global biotech CDMO contracts with overlapping mAb and bispecific capabilities.
- WuXi Biologics: China-headquartered, Hong Kong-listed global biologics CDMO offering end-to-end services from cell line development through commercial manufacturing. The most direct competitor to Chime Biologics in terms of geographic origin, service portfolio, and target customer base, with materially larger scale (~600,000L capacity).
- AGC Biologics: Global biologics CDMO with manufacturing sites in the US, Europe, and Japan, offering mammalian and microbial-based biologics development and manufacturing services. Comparable mid-large tier peer competing for similar global biotech CDMO engagements.
- Bora Pharmaceuticals: Taiwan-headquartered CDMO with rapidly expanding biologics manufacturing capabilities alongside its established small-molecule franchise. Emerging direct competitor in Asia-Pacific biologics CDMO space with similar growth-oriented capacity expansion trajectory.
- KBI Biopharma: US-headquartered biologics CDMO (acquired by JSR Life Sciences) offering process development, analytical services, and cGMP manufacturing. Comparable mid-tier peer with similar focus on mammalian cell-based biologics and competitive pressure in the same customer segment.
- Boehringer Ingelheim BioXcellence: German-headquartered biologics CDMO division of Boehringer Ingelheim offering contract manufacturing from cell line through commercial supply. Direct peer with comparable service portfolio and similar positioning in mammalian-cell biologics manufacturing for global biotech clients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Chime Biologics social profiles
Digital presenceChime Biologics compliance and trust
Trust signalCompliance6 records
Chime Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Chime Biologics leadership team
Management profileNumber of profiles
Profiles4 records
Chime Biologics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Chime Biologics M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Chime Biologics
What does Chime Biologics do?
Chime Biologics is a global Contract Development and Manufacturing Organization (CDMO) that provides end-to-end biologics manufacturing services for biotech and pharmaceutical companies. The company offers services spanning cell line development, process development, drug substance manufacturing (50L–2000L), drug product manufacturing, technology transfer, quality control, and regulatory support from pre-clinical through commercial stages. Its operations leverage the world's first GE KuBio modular biopharmaceutical manufacturing facility using single-use bioprocessing technology, complemented by the newly launched Chime AI Platform for AI-driven biologics discovery and development.
Is Chime Biologics a public or private company?
Chime Biologics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Chime Biologics founded?
Chime Biologics was founded in 2013. It employs 501 to 1,000 people.
Where is Chime Biologics based?
Chime Biologics is headquartered in Wuhan, China, in the Asia region.
How does Chime Biologics make money?
One revenue line is on record: CDMO Contract Manufacturing Services.
Who are Chime Biologics's main competitors?
Broad incumbents on record are Lonza and Catalent. Direct peers are Samsung Biologics, WuXi Biologics, AGC Biologics, Bora Pharmaceuticals, KBI Biopharma and Boehringer Ingelheim BioXcellence.
Does Chime Biologics have an API?
No public API is recorded for Chime Biologics.
What industry is Chime Biologics in?
Chime Biologics's product category is Biopharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAAAKAA, Biologic API/Drug Substance Manufacturing Services. Its NAICS code is 541714 and its SIC code is 8731.